CD14- mononuclear stromal cells support (CD14+) monocyte-osteoclast differentiation in aneurysmal bone cyst

Laboratory Investigation

Volumn 92, Issue 4, 2012, Pages 600-605

  Taylor, Richard M I ^a   Kashima, Takeshi G ^a   Hemingway, Francesca K E ^a   Dongre, Arundhati ^a   Knowles, Helen J ^a   Athanasou, Nicholas A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

aneurysmal bone cyst (ABC); bisophosphonate; bone resorption; giant cell; osteoclast

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CALCITONIN; CATHEPSIN K; CD14 ANTIGEN; CD51 ANTIGEN; COLONY STIMULATING FACTOR 1; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; ZOLEDRONIC ACID;

ANEURYSMAL BONE CYST; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; GIANT CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOLECULAR MECHANICS; MONOCYTE; MONOCYTE MACROPHAGE PRECURSOR CELL; OSTEOCLAST; OSTEOLYSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA CELL;

ADOLESCENT; ADULT; ANTIGENS, CD14; BONE CYSTS, ANEURYSMAL; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CHILD; CHILD, PRESCHOOL; FEMALE; GIANT CELLS; HUMANS; MACROPHAGE COLONY-STIMULATING FACTOR; MALE; MIDDLE AGED; MONOCYTES; OSTEOCLASTS; OSTEOPROTEGERIN; PHENOTYPE; RANK LIGAND; YOUNG ADULT;

EID: 84859299658     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2012.5     Document Type: Article

References (27)

1. Rosenberg AE, GP N, Fletcher J. Aneurysmal bone cyst. In: Fletcher C, Unni K, Mertens F (eds) Pathology and Genetics of Tumours of Soft Tissue and Bone. IARC: Lyon, 2002, pp 338-339.
2. th edn. AFIP: Washington DC, 2005, pp 281-298.
3. Oliveira AM, Hsi BL, Weremowicz S, et al. USP6 (Tre2) fusion oncogenes in aneurysmal bone cyst. Cancer Res 2004;64:1920-1923. (Pubitemid 38339434)
4. Oliveira AM, Perez-Atayde AR, Inwards CY, et al. USP6 and CDH11 oncogenes identify the neoplastic cell in primary aneurysmal bone cysts and are absent in so-called secondary aneurysmal bone cysts. Am J Pathol 2004;165:1773-1780. (Pubitemid 39435174)
5. Panoutsakopoulos G, Pandis N, Kyriazoglou I, et al. Recurrent t(16;17)(q22;p13) in aneurysmal bone cysts. Genes Chromosomes Cancer 1999;26:265-266. (Pubitemid 29468348)
6. Athanasou NA. Cellular biology of bone-resorbing cells. J Bone Joint Surg Am 1996;78:1096-1112.
7. Fujikawa Y, Quinn JM, Sabokbar A, et al. The human osteoclast precursor circulates in the monocyte fraction. Endocrinology 1996;137:4058-4060. (Pubitemid 26284685)
8. Quinn JM, Elliott J, Gillespie MT, et al. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology 1998;139:4424-4427. (Pubitemid 28513734)
9. Tanaka S, Takahashi N, Udagawa N, et al. Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J Clin Invest 1993;91:257-263. (Pubitemid 23037280)
10. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95:3597-3602.
11. Lau YS, Sabokbar A, Gibbons CL, et al. Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue. Hum Pathol 2005;36:945-954. (Pubitemid 41253379)
12. Minkin C. Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int 1982;34:285-290. (Pubitemid 12060442)
13. Athanasou NA, Quinn J. Immunophenotypic differences between osteoclasts and macrophage polykaryons: immunohistological distinction and implications for osteoclast ontogeny and function. J Clin Pathol 1990;43:997-1003.
14. Horton MA, Lewis D, McNulty K, et al. Monoclonal antibodies to osteoclastomas (giant cell bone tumors): definition of osteoclast-specific cellular antigens. Cancer Res 1985;45(Pt 2):5663-5669. (Pubitemid 16218570)
15. Chambers TJ, Horton MA. Failure of cells of the mononuclear phagocyte series to resorb bone. Calcif Tissue Int 1984;36:556-558. (Pubitemid 15157109)
16. Faust J, Lacey DL, Hunt P, et al. Osteoclast markers accumulate on cells developing from human peripheral blood mononuclear precursors. J Cell Biochem 1999;72:67-80. (Pubitemid 28541482)
17. Huang L, Cheng YY, Chow LT, et al. Receptor activator of NF-kappaB ligand (RANKL) is expressed in chondroblastoma: possible involvement in osteoclastic giant cell recruitment. Mol Pathol 2003;56:116-120. (Pubitemid 36461472)
18. Itonaga I, Hussein I, Kudo O, et al. Cellular mechanisms of osteoclast formation and lacunar resorption in giant cell granuloma of the jaw. J Oral Pathol Med 2003;32:224-231. (Pubitemid 36604018)
19. Won KY, Kalil RK, Kim YW, et al. RANK signalling in bone lesions with osteoclast-like giant cells. Pathology 2011;43:318-321.
20. Motoyoshi K. Biological activities and clinical application of M-CSF. Int J Hematol 1998;67:109-122. (Pubitemid 28248381)
21. Tsurukai T, Udagawa N, Matsuzaki K, et al. Roles of macrophage-colony stimulating factor and osteoclast differentiation factor in osteoclastogenesis. J Bone Miner Metab 2000;18:177-184. (Pubitemid 30431779)
22. Ye Y, Pringle LM, Lau AW, et al. TRE17/USP6 oncogene translocated in aneurysmal bone cyst induces matrix metalloproteinase production via activation of NF-kappaB. Oncogene 2010;29:3619-3629.
23. Harmey D, Stenbeck G, Nobes CD, et al. Regulation of osteoblast differentiation by Pasteurella multocida toxin (PMT): a role for Rho GTPase in bone formation. J Bone Miner Res 2004;19:661-670. (Pubitemid 41071227)
24. Reid IR. Bisphosphonates. Skeletal Radiol 2007;36:711-714. (Pubitemid 47009815)
25. Hofbauer LC, Khosla S, Dunstan CR, et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000;15:2-12. (Pubitemid 30026926)
26. Balke M, Campanacci L, Gebert C, et al. Bisphosphonate treatment of aggressive primary, recurrent and metastatic giant cell tumour of bone. BMC Cancer 2010;10:462.
27. Thomas D, Henshaw R, Skubitz K, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 2010;11:275-280.